General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials

被引:32
|
作者
Dmitrienko, Alex [1 ]
Muysers, Christoph [2 ]
Fritsch, Arno [3 ]
Lipkovich, Ilya
机构
[1] Quintiles, Ctr Stat Drug Dev, 6700 W 115th St, Overland Pk, KS 66209 USA
[2] Bayer HealthCare, Clin Stat, Berlin, Germany
[3] Bayer HealthCare, Clin Stat, Wuppertal, Germany
关键词
Biomarker evaluation; enrichment designs; regulatory guidance; subgroup analysis; subgroup identification; FRACTIONAL POLYNOMIALS; REGULATORY ISSUES; ADAPTIVE DESIGNS; SELECTION; IDENTIFICATION; CONSISTENCY; BIOMARKERS; FRAMEWORK;
D O I
10.1080/10543406.2015.1092033
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This article focuses on a broad class of statistical and clinical considerations related to the assessment of treatment effects across patient subgroups in late-stage clinical trials. This article begins with a comprehensive review of clinical trial literature and regulatory guidelines to help define scientifically sound approaches to evaluating subgroup effects in clinical trials. All commonly used types of subgroup analysis are considered in the article, including different variations of prospectively defined and post-hoc subgroup investigations. In the context of confirmatory subgroup analysis, key design and analysis options are presented, which includes conventional and innovative trial designs that support multi-population tailoring approaches. A detailed summary of exploratory subgroup analysis (with the purpose of either consistency assessment or subgroup identification) is also provided. The article promotes a more disciplined approach to post-hoc subgroup identification and formulates key principles that support reliable evaluation of subgroup effects in this setting.
引用
收藏
页码:71 / 98
页数:28
相关论文
共 50 条
  • [11] Trials within trials:: Confirmatory subgroup analyses in controlled clinical experiments
    Moyé, LA
    Deswal, A
    CONTROLLED CLINICAL TRIALS, 2001, 22 (06): : 605 - 619
  • [12] Migraine mAbs crowd into late-stage trials
    Gunjan Sinha
    Nature Biotechnology, 2015, 33 : 676 - 677
  • [13] Migraine mAbs crowd into late-stage trials
    Sinha, Gunjan
    NATURE BIOTECHNOLOGY, 2015, 33 (07) : 676 - 677
  • [14] Flexible Bayesian subgroup analysis in early and confirmatory trials
    Bunn, Veronica
    Liu, Rachael
    Lin, Junjing
    Lin, Jianchang
    CONTEMPORARY CLINICAL TRIALS, 2020, 98
  • [15] Data-Driven Subgroup Identification in Confirmatory Clinical Trials
    Bunouf, Pierre
    Groc, Melanie
    Dmitrienko, Alex
    Lipkovich, Ilya
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2022, 56 (01) : 65 - 75
  • [16] Subgroup selection in adaptive signature designs of confirmatory clinical trials
    Zhang, Zhiwei
    Li, Meijuan
    Lin, Min
    Soon, Guoxing
    Greene, Tom
    Shen, Changyu
    JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS, 2017, 66 (02) : 345 - 361
  • [17] Data-Driven Subgroup Identification in Confirmatory Clinical Trials
    Pierre Bunouf
    Mélanie Groc
    Alex Dmitrienko
    Ilya Lipkovich
    Therapeutic Innovation & Regulatory Science, 2022, 56 : 65 - 75
  • [18] NCI begins overhaul of late-stage cancer trials
    Alicia Ault
    Nature Medicine, 1998, 4 : 1219 - 1219
  • [19] NCI begins overhaul of late-stage cancer trials
    Ault, A
    NATURE MEDICINE, 1998, 4 (11) : 1219 - 1219
  • [20] The inclusion of pregnant women in vaccine clinical trials: An overview of late-stage clinical trials' records between 2018 and 2023
    Salloum, Maha
    Paviotti, Antea
    Bastiaens, Hilde
    Van Geertruyden, Jean-Pierre
    VACCINE, 2023, 41 (48) : 7076 - 7083